Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

These are exciting times for cancer immunotherapy. After many years of disappointing
results, the tide has finally changed and immunotherapy has become a clinically validated …

Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent …

Approximately one‐half of patients with newly diagnosed cancer and many patients with
persistent or recurrent tumors receive radiotherapy (RT), with the explicit goal of eliminating …

Genetic instability of tumor cells often leads to the occurrence of a large number of
mutations, and expression of non-synonymous mutations can produce tumor-specific …

Activating the immune system for therapeutic benefit in cancer has long been a goal in
immunology and oncology. After decades of disappointment, the tide has finally changed …

Abstract Galectin-3 is a 31-kDa lectin that modulates T-cell responses through several
mechanisms, including apoptosis, T-cell receptor (TCR) cross-linking, and TCR …

Conventional cytotoxic cancer chemotherapy is often immunosuppressive and associated
with drug resistance and tumor regrowth after a short period of tumor shrinkage or growth …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Pancreatic ductal adenocarcinoma (PDA) has a poor prognosis due to late detection and
resistance to conventional therapies. Published studies show that the PDA tumor …